A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19

Purpose

The primary objective of this study is to describe the longevity of IgG against SARS-CoV-2 infection or vaccination.

Condition

  • SARS-CoV-2 Acute Respiratory Disease

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Age ≥ 18 years - Willing to provide informed consent prior to participation. - Cohort 1 (Arm 1) - Positive test results for SARS-CoV-2 virus by an RT-PCR or Antigen test AND not received any COVID-19 vaccine or participated in any COVID-19 vaccine trial - Cohort 2 (Arm 2) - Received the COVID-19 vaccine

Exclusion Criteria

  • Unable or unwilling to provide informed consent - Individuals with known conditions or treatments associated with immune impairment, such as cancer and chemotherapy

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Other

Arm Groups

ArmDescriptionAssigned Intervention
Unvaccinated SARS-CoV-2 positive Participants who have tested positive for SARS-CoV-2, both with and without symptoms, who have not been vaccinated
  • Other: SARS-CoV-2
    Observational
Vaccinated Participants who were vaccinated against SARS-CoV-2
  • Other: SARS-CoV-2
    Observational

Recruiting Locations

More Details

NCT ID
NCT05042193
Status
Completed
Sponsor
Everly Health

Detailed Description

This virtual clinical study will use a prospective design, to evaluate longevity and seroprevalence of IgG against SARS-CoV-2 in approximately 800 patients as measured by Dried Blood Spots via fingerstick using the Everlywell COVID-19 Antibody Test Home Collection Kit. Participants will be followed up to 9 months at 1, 3, 6 and 9 months after enrollment.